Omeros Corporation (OMER)
| Market Cap | 472.59M |
| Revenue (ttm) | 86.63M |
| Net Income (ttm) | -139.42M |
| Shares Out | 62.37M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,354,631 |
| Open | 7.88 |
| Previous Close | 7.73 |
| Day's Range | 7.40 - 7.99 |
| 52-Week Range | 6.51 - 23.85 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 40.40 (+422.6%) |
| Est. Earnings Date | Nov 8, 2021 |
About OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HS...
Financial Performance
In 2020, Omeros's revenue was $73.81 million, a decrease of -33.98% compared to the previous year's $111.81 million. Losses were -$138.06 million, 63.4% more than in 2019.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Omeros stock is "Buy." The 12-month stock price forecast is 40.40, which is an increase of 422.64% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to cont...
OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and En...
NEW YORK--(BUSINESS WIRE)-- #Omeros--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Comp...
OMER EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investors with Losses to Inquire Ab...
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (...
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encoura...
LOS ANGELES, Oct. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation ("Ome...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER...
LOS ANGELES--(BUSINESS WIRE)---- $OMER #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Inve...
BENSALEM, Pa.--(BUSINESS WIRE)---- $OMER #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) investors conc...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encou...
LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourag...
LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.
OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire Abo...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (NASDAQ: OMER...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors ar...
OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today
Today, some rather unfortunate news has come to light regarding one of Omeros' prospective drugs, taking OMER stock 40% lower. The post OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today a...
Here's why Omeros Corp shares are down 40% on Friday morning
The U.S. FDA notified Omeros Corporation (NASDAQ: OMER) that it identified deficiencies in the company's marketing application for Narsoplimab, Omeros disclosed in a press release this morning. Shares...
Here's Why Omeros Stock Is Tanking Today
The narsoplimab program hasn't proceeded as swimmingly as investors thought.
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA's ongoing review of the company's B...
Why Omeros Stock Is Plummeting This Week
The biotech stock was part of a larger Wall Street sell-off.
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Omeros: Q2 Earnings Insights
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the esti...
Omeros Corporation Reports Second Quarter 2021 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 202...
Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-assoc...
Omeros' Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell tra...
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
Omeros (OMER) announces initial results from a phase I study of OMS906.
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...